Skip to main content
SpringerLink
Log in
Book cover

Primary Liver Cancer pp 19–44Cite as

Systemic Dysregulation in the Development of Hepatocellular Carcinoma

  • Chapter

  • 1272 Accesses

Abstract

Cancer is an ancient disease of multi-cellular organisms acquired in the history of evolution. For more than one century, cancer was defined as a disease of autonomous, abnormal growth of cells from an organ or tissue. Therefore, the majority of research and resources were focused on the cancer, especially cancer cells. In recent decades, an increasing body of evidence has emerged to indicate that carcinogenesis and cancer progressions involve systemic dysregulation, which may be the important driving force in cancer development as well as its progression. As we have emphasized in Chapter 1, we defined cancer as a systems disease which is characterized by abnormal cell growth in a defined tissue or organ and progressive systemic dysregulation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antoni M H, Lutgendorf S K, Cole S W, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer, 2006, 6: 240–248.

    Article  PubMed  CAS  Google Scholar 

  2. Yuen M F, Hou J L, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 2009, 24: 346–353.

    Article  PubMed  Google Scholar 

  3. Luo R H, Zhao Z X, Zhou X Y, et al. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol, 2005, 11: 4431–4434.

    PubMed  Google Scholar 

  4. Laconi E, Tomasi C, Curreli F, et al. Early exposure to restraint stress enhances chemical carcinogenesis in rat liver. Cancer Lett, 2000, 161: 215–220.

    Article  PubMed  CAS  Google Scholar 

  5. Cao L, Liu X, Lin E J, et al. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell, 2010, 142: 52–64.

    Article  PubMed  CAS  Google Scholar 

  6. Clevenger C V, Furth P A, Hankinson S E, et al. The role of prolactin in mammary carcinoma. Endocr Rev, 2003, 24: 1–27.

    Article  PubMed  CAS  Google Scholar 

  7. Pequeux C, Keegan B P, Hagelstein M T, et al. Oxytocin-and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer, 2004, 11: 871–885.

    Article  PubMed  CAS  Google Scholar 

  8. Thaker P H, Han L Y, Kamat A A, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med, 2006, 12: 939–944.

    Article  PubMed  CAS  Google Scholar 

  9. Wan D, Gong Y, Qin W, et al. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci USA, 2004, 101: 15724–15729.

    Article  PubMed  CAS  Google Scholar 

  10. Wang Y, Wang T, Shi X, et al. Analysis of acetylcholine, choline and butyrobetaine in human liver tissues by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal, 2008, 47: 870–875.

    Article  PubMed  CAS  Google Scholar 

  11. Oben J A, Diehl A M. Sympathetic nervous system regulation of liver repair. Anat Rec A Discov Mol Cell Evol Biol, 2004, 280: 874–883.

    Article  PubMed  Google Scholar 

  12. Wessler I, Kirkpatrick C J, Racke K. The cholinergic ‘pitfall’: acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol, 1999, 26: 198–205.

    Article  PubMed  CAS  Google Scholar 

  13. Wessler I, Kilbinger H, Bittinger F, et al. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci, 2003, 72: 2055–2061.

    Article  PubMed  CAS  Google Scholar 

  14. Wessler I, Kirkpatrick C J, Racke K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther, 1998, 77: 59–79.

    Article  PubMed  CAS  Google Scholar 

  15. Klein J, Holler T, Cappel E, et al. Release of choline from rat brain under hypoxia: contribution from phospholipase A2 but not from phospholipase D. Brain Res, 1993, 630: 337–340.

    Article  PubMed  CAS  Google Scholar 

  16. Song P, Sekhon H S, Jia Y, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res, 2003, 63: 214–221.

    PubMed  CAS  Google Scholar 

  17. Trombino S, Cesario A, Margaritora S, et al. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res, 2004, 64: 135–145.

    Article  PubMed  CAS  Google Scholar 

  18. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol, 2004, 74: 363–396.

    Article  PubMed  CAS  Google Scholar 

  19. Leonard S, Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob Res, 2001, 3: 203–223.

    Article  PubMed  CAS  Google Scholar 

  20. Brejc K, Van Dijk W J, Klaassen R V, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature, 2001, 411: 269–276.

    Article  PubMed  CAS  Google Scholar 

  21. Moise L, Piserchio A, Basus V J, et al. NMR structural analysis of alpha-bungarotoxin and its complex with the principal alpha-neurotoxinbinding sequence on the alpha 7 subunit of a neuronal nicotinic acetylcholine receptor. J Biol Chem, 2002, 277: 12406–12417.

    Article  PubMed  CAS  Google Scholar 

  22. Antil S, Servent D, Menez A. Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of alpha-cobratoxin. J Biol Chem, 1999, 274: 34851–34858.

    Article  PubMed  CAS  Google Scholar 

  23. Berg D K, Conroy W G. Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol, 2002, 53: 512–523.

    Article  PubMed  CAS  Google Scholar 

  24. Couturier S, Bertrand D, Matter J M, et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron, 1990, 5: 847–856.

    Article  PubMed  CAS  Google Scholar 

  25. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci, 2004, 25: 317–324.

    Article  PubMed  CAS  Google Scholar 

  26. Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature, 2003, 423: 949–955.

    Article  PubMed  CAS  Google Scholar 

  27. Fucile S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium, 2004, 35: 1–8.

    Article  PubMed  CAS  Google Scholar 

  28. Berridge M J, Lipp P, Bootman M D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol, 2000, 1: 11–21.

    Article  PubMed  CAS  Google Scholar 

  29. Thomas A P, Bird G S, Hajnoczky G, et al. Spatial and temporal aspects of cellular calcium signaling. FASEB J, 1996, 10: 1505–1517.

    PubMed  CAS  Google Scholar 

  30. Albuquerque E X, Pereira E F, Alkondon M, et al. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. J Recept Signal Transduct Res, 1997, 17: 243–266.

    Article  PubMed  CAS  Google Scholar 

  31. Lev S, Moreno H, Martinez R, et al. Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions. Nature, 1995, 376: 737–745.

    Article  PubMed  CAS  Google Scholar 

  32. Nakayama H, Numakawa T, Ikeuchi T, et al. Nicotine-induced phosphorylation of extracellular signal-regulated protein kinase and CREB in PC12h cells. J Neurochem, 2001, 79: 489–498.

    Article  PubMed  CAS  Google Scholar 

  33. Dajas-Bailador F A, Soliakov L, Wonnacott S. Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem, 2002, 80: 520–530.

    Article  PubMed  CAS  Google Scholar 

  34. Sastry B V, Janson V E. Cholinergic markers in transformed trophoblast cells: BeWo and JAr cells. Cell Mol Biol (Noisy-le-grand), 1997, 43: 559–565.

    CAS  Google Scholar 

  35. Kamimura Y, Fujii T, Kojima H, et al. Nitric oxide (NO) synthase mRNA expression and NO production via muscarinic acetylcholine receptor-mediated pathways in the CEM, human leukemic T-cell line. Life Sci, 2003, 72: 2151–2154.

    Article  PubMed  CAS  Google Scholar 

  36. Zhao Y J, Wang X Y, Wang T, et al. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology, 2011, 53: 493–503.

    Article  PubMed  CAS  Google Scholar 

  37. Ahlquist R P. A study of the adrenotropic receptors. Am J Physiol, 1948, 153: 586–600.

    PubMed  CAS  Google Scholar 

  38. Aantaa R, Jalonen J. Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol, 2006, 23: 361–372.

    Article  PubMed  CAS  Google Scholar 

  39. Hein L, Altman J D, Kobilka B K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature, 1999, 402: 181–184.

    Article  PubMed  CAS  Google Scholar 

  40. Dixon R A, Kobilka B K, Strader D J, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature, 1986, 321: 75–79.

    Article  PubMed  CAS  Google Scholar 

  41. Kobilka B K, Dixon R A, Frielle T, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA, 1987, 84: 46–50.

    Article  PubMed  CAS  Google Scholar 

  42. Kyprianou N, Benning C M. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res, 2000, 60: 4550–4555.

    PubMed  CAS  Google Scholar 

  43. Benning C M, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptorindependent action. Cancer Res, 2002, 62: 597–602.

    PubMed  CAS  Google Scholar 

  44. Siddiqui E J, Shabbir M, Thompson C S, et al. Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res, 2005, 25: 4281–4286.

    PubMed  CAS  Google Scholar 

  45. Lin S C, Chueh S C, Hsiao C J, et al. Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia, 2007, 9: 830–839.

    Article  PubMed  CAS  Google Scholar 

  46. Liou S F, Lin H H, Liang J C, et al. Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis. Toxicology, 2009, 256: 13–24.

    Article  PubMed  CAS  Google Scholar 

  47. Kanda H, Ishii K, Ogura Y, et al. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer, 2008, 122: 444–451.

    Article  PubMed  CAS  Google Scholar 

  48. Tatsuta M, Iishi H, Baba M, et al. Alpha 1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N′-nitro-Nnitrosoguanidine in Wistar rats. Int J Cancer, 1998, 77: 467–469.

    Article  PubMed  CAS  Google Scholar 

  49. Al-Wadei H A, Schuller H M. Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol, 2009, 218: 437–445.

    Article  PubMed  CAS  Google Scholar 

  50. Park P G, Merryman J, Orloff M, et al. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res, 1995, 55: 3504–3508.

    PubMed  CAS  Google Scholar 

  51. Cruise J L, Knechtle S J, Bollinger R R, et al. Alpha 1-adrenergic effects and liver regeneration. Hepatology, 1987, 7: 1189–11894.

    Article  PubMed  CAS  Google Scholar 

  52. Cruise J L, Houck K A, Michalopoulos G K. Induction of DNA synthesis in cultured rat hepatocytes through stimulation of alpha 1 adrenoreceptor by norepinephrine. Science, 1985, 227: 749–751.

    Article  PubMed  CAS  Google Scholar 

  53. Bevilacqua M, Norbiato G, Chebat E, et al. Changes in alpha-1 and beta-2 adrenoceptor density in human hepatocellular carcinoma. Cancer, 1991, 67: 2543–2551.

    Article  PubMed  CAS  Google Scholar 

  54. Leung T W, Yu S, Johnson P J, et al. Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. J Clin Oncol, 2003, 21: 652–658.

    Article  PubMed  CAS  Google Scholar 

  55. Cavalheiro Ea L J, Turski L. Frontiers in excitatory amino acid research. New York: Alan R Liss, 1988.

    Google Scholar 

  56. Watkins J C, Evans R H. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol, 1981, 21: 165–204.

    Article  PubMed  CAS  Google Scholar 

  57. Beart P M, O’shea R D. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol, 2007, 150: 5–17.

    Article  PubMed  CAS  Google Scholar 

  58. Kanai Y, Hediger M A. The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. Eur J Pharmacol, 2003, 479: 237–247.

    Article  PubMed  CAS  Google Scholar 

  59. Sato H, Tamba M, Ishii T, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem, 1999, 274: 11455–11458.

    Article  PubMed  CAS  Google Scholar 

  60. Sato H, Tamba M, Kuriyama-Matsumura K, et al. Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc. Antioxid Redox Signal, 2000, 2: 665–571.

    Article  PubMed  CAS  Google Scholar 

  61. Kim J Y, Kanai Y, Chairoungdua A, et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta, 2001, 1512: 335–344.

    Article  PubMed  CAS  Google Scholar 

  62. Okuno S, Sato H, Kuriyama-Matsumura K, et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer, 2003, 88: 951–956.

    Article  PubMed  CAS  Google Scholar 

  63. Huang Y, Dai Z, Barbacioru C, et al. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res, 2005, 65: 7446–7454.

    Article  PubMed  CAS  Google Scholar 

  64. Pin J P, Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord, 2002, 1: 297–317.

    Article  PubMed  CAS  Google Scholar 

  65. Schoepp D D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther, 2001, 299: 12–20.

    PubMed  CAS  Google Scholar 

  66. Ye Z C, Rothstein J D, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci, 1999, 19: 10767–10777.

    PubMed  CAS  Google Scholar 

  67. Ye Z C, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res, 1999, 59: 4383–4391.

    PubMed  CAS  Google Scholar 

  68. Gegelashvili G, Civenni G, Racagni G, et al. Glutamate receptor agonists up-regulate glutamate transporter GLAST in astrocytes. Neuroreport, 1996, 8: 261–265.

    Article  PubMed  CAS  Google Scholar 

  69. Gegelashvili G, Dehnes Y, Danbolt N C, et al. The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signalling mechanisms. Neurochem Int, 2000, 37: 163–170.

    Article  PubMed  CAS  Google Scholar 

  70. Lyons S A, Chung W J, Weaver A K, et al. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res, 2007, 67: 9463–9471.

    Article  PubMed  CAS  Google Scholar 

  71. Ishiuchi S, Tsuzuki K, Yoshida Y, et al. Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med, 2002, 8: 971–978.

    Article  PubMed  CAS  Google Scholar 

  72. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA, 2001, 98: 6372–6377.

    Article  PubMed  CAS  Google Scholar 

  73. D’onofrio M, Arcella A, Bruno V, et al. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem, 2003, 84: 1288–1295.

    Article  CAS  Google Scholar 

  74. Pollock P M, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet, 2003, 34: 108–112.

    Article  PubMed  CAS  Google Scholar 

  75. Iacovelli L, Arcella A, Battaglia G, et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci, 2006, 26: 8388–8397.

    Article  PubMed  CAS  Google Scholar 

  76. Yoo B C, Jeon E, Hong S H, et al. Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res, 2004, 10: 4176–4184.

    Article  PubMed  CAS  Google Scholar 

  77. Chang H J, Yoo B C, Lim S B, et al. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res, 2005, 11: 3288–3295.

    Article  PubMed  CAS  Google Scholar 

  78. Park S Y, Lee S A, Han I H, et al. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep, 2007, 17: 81–87.

    PubMed  Google Scholar 

  79. Chen R S, Song Y M, Zhou Z Y, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene, 2009, 28: 599–609.

    Article  PubMed  CAS  Google Scholar 

  80. Yang Y, Li C, Nie X, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res, 2007, 6: 2605–2614.

    Article  PubMed  CAS  Google Scholar 

  81. Watanabe M, Maemura K, Kanbara K, et al. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol, 2002, 213: 1–47.

    Article  PubMed  CAS  Google Scholar 

  82. Johnston G A. GABAA receptor pharmacology. Pharmacol Ther, 1996, 69: 173–198.

    Article  PubMed  CAS  Google Scholar 

  83. Davies P A, Hanna M C, Hales T G, et al. Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Nature, 1997, 385: 820–823.

    Article  PubMed  CAS  Google Scholar 

  84. Mehta A K, Ticku M K. An update on GABAA receptors. Brain Res Brain Res Rev, 1999, 29: 196–217.

    Article  PubMed  CAS  Google Scholar 

  85. Kaupmann K, Huggel K, Heid J, et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature, 1997, 386: 239–246.

    Article  PubMed  CAS  Google Scholar 

  86. Bettler B, Tiao J Y. Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther, 2006, 110: 533–543.

    Article  PubMed  CAS  Google Scholar 

  87. Tatsuta M, Iishi H, Baba M, et al. Effect of gamma-butyrolactone on baclofen inhibition of gastric carcinogenesis induced by N-methyl-N’-nitro-N-nitrosoguanidine in Wistar rats. Oncology, 1992, 49: 123–126.

    Article  PubMed  CAS  Google Scholar 

  88. Tatsuta M, Iishi H, Baba M, et al. Attenuation by the GABA receptor agonist baclofen of experimental carcinogenesis in rat colon by azoxymethane. Oncology, 1992, 49: 241–245.

    Article  PubMed  CAS  Google Scholar 

  89. Kleinrok Z, Matuszek M, Jesipowicz J, et al. GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s.c. tumors in athymic nu/nu mice. J Physiol Pharmacol, 1998, 49: 303–310.

    PubMed  CAS  Google Scholar 

  90. Maemura K, Yamauchi H, Hayasaki H, et al. Gamma-amino-butyric acid immunoreactivity in intramucosal colonic tumors. J Gastroenterol Hepatol, 2003, 18: 1089–1094.

    Article  PubMed  CAS  Google Scholar 

  91. Opolski A, Mazurkiewicz M, Wietrzyk J, et al. The role of GABA-ergic system in human mammary gland pathology and in growth of transplantable murine mammary cancer. J Exp Clin Cancer Res, 2000, 19: 383–390.

    PubMed  CAS  Google Scholar 

  92. Matuszek M, Jesipowicz M, Kleinrok Z. GABA content and GAD activity in gastric cancer. Med Sci Monit, 2001, 7: 377–381.

    PubMed  CAS  Google Scholar 

  93. Bianchi L, De Micheli E, Bricolo A, et al. Extracellular levels of amino acids and choline in human high grade gliomas: an intraoperative microdialysis study. Neurochem Res, 2004, 29: 325–334.

    Article  PubMed  CAS  Google Scholar 

  94. Roberts S S, Mori M, Pattee P, et al. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol, 2004, 22: 4127–4134.

    Article  PubMed  CAS  Google Scholar 

  95. Jiang Y, Harlocker S L, Molesh D A, et al. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene, 2002, 21: 2270–2282.

    Article  PubMed  CAS  Google Scholar 

  96. Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res, 2007, 67: 9704–9712.

    Article  PubMed  CAS  Google Scholar 

  97. Azuma H, Inamoto T, Sakamoto T, et al. Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res, 2003, 63: 8090–8096.

    PubMed  CAS  Google Scholar 

  98. Joseph J, Niggemann B, Zaenker K S, et al. The neurotransmitter gammaaminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res, 2002, 62: 6467–6469.

    PubMed  CAS  Google Scholar 

  99. Fava G, Marucci L, Glaser S, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res, 2005, 65: 11437–11446.

    Article  PubMed  CAS  Google Scholar 

  100. Thaker P H, Yokoi K, Jennings N B, et al. Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. Cancer Biol Ther, 2005, 4: 753–758.

    Article  PubMed  CAS  Google Scholar 

  101. Zhang M, Gong Y, Assy N, et al. Increased GABAergic activity inhibits alpha-fetoprotein mRNA expression and the proliferative activity of the HepG2 human hepatocellular carcinoma cell line. J Hepatol, 2000, 32: 85–91.

    Article  PubMed  CAS  Google Scholar 

  102. Minuk G Y, Zhang M, Gong Y, et al. Decreased hepatocyte membrane potential differences and GABAA-beta3 expression in human hepatocellular carcinoma. Hepatology, 2007, 45: 735–745.

    Article  PubMed  CAS  Google Scholar 

  103. Wang T, Huang W, Chen F. Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo. Life Sci, 2008, 82: 536–541.

    Article  PubMed  CAS  Google Scholar 

  104. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol, 2004, 4: 941–952.

    Article  PubMed  CAS  Google Scholar 

  105. Gao F G, Wan Da F, Gu J R. Ex vivo nicotine stimulation augments the efficacy of therapeutic bone marrow-derived dendritic cell vaccination. Clin Cancer Res, 2007, 13: 3706–3712.

    Article  PubMed  CAS  Google Scholar 

  106. Gao F G, Li H T, Li Z J, et al. Nicotine Stimulated Dendritic Cells Could Achieve Anti-Tumor Effects in Mouse Lung and Liver Cancer. J Clin Immunol, 2011, 31: 80–88.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No.25/Ln.2200, Xie Tu Road, Shanghai, 200032, China

    Jianren Gu, Xianghuo He, Zhenfeng Zhang, Weijie Guo, Zhiao Chen & Yingjun Zhao

Authors
  1. Jianren Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xianghuo He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhenfeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weijie Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yingjun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gu, J., He, X., Zhang, Z., Guo, W., Chen, Z., Zhao, Y. (2012). Systemic Dysregulation in the Development of Hepatocellular Carcinoma. In: Primary Liver Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28702-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-28702-2_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-28701-5

  • Online ISBN: 978-3-642-28702-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation